Trial Profile
A study evaluating Sorafenib maintenance therapy for patients with FLT3-ITD acute myeloid leukaemia after allogeneic stem cell transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 19 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association